Cerevel Therapeutics Holdings (STU:673) Long-Term Capital Lease Obligation : €24.72 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings Long-Term Capital Lease Obligation?

Cerevel Therapeutics Holdings's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €24.72 Mil.

Cerevel Therapeutics Holdings's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€26.87 Mil) to Dec. 2023 (€25.48 Mil) and declined from Dec. 2023 (€25.48 Mil) to Mar. 2024 (€24.72 Mil).

Cerevel Therapeutics Holdings's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€30.19 Mil) to Dec. 2022 (€29.44 Mil) and declined from Dec. 2022 (€29.44 Mil) to Dec. 2023 (€25.48 Mil).

Cerevel Therapeutics Holdings Long-Term Capital Lease Obligation Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Long-Term Capital Lease Obligation Chart

Cerevel Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

23.24

25.46

30.19

29.44

25.48

Cerevel Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial													28.38	27.26	26.87	25.48	24.72

Cerevel Therapeutics Holdings (STU:673) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Cerevel Therapeutics Holdings Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CERE:USA

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines